If you are currently being treated with nilotinib as 2nd or 1st line therapy and you are willing to share your experience by taking part in detailed telephone interviews, then please contact me on cmlsupportgroup@gmail.com by end of 11th November and I will pass your contact details on.
The interviews are to be used to compile a series of more accurate case studies that better reflect the reality of how patients are actually responding to nilotinib.
Sandy